DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment

IF 6.9 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Biomedicine & Pharmacotherapy Pub Date : 2024-09-25 DOI:10.1016/j.biopha.2024.117464

Xin Guo , Huolun Feng , Liyang Cai , Jiabin Zheng , Yong Li

{"title":"DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment","authors":"Xin Guo , Huolun Feng , Liyang Cai , Jiabin Zheng , Yong Li","doi":"10.1016/j.biopha.2024.117464","DOIUrl":null,"url":null,"abstract":"<div><div>Along with social development and lifestyle changes, the number of overweight and obese patients worldwide is rising annually. Obesity is a chronic metabolic disease with complex etiology. Dipeptidyl peptidase IV (DPP-IV) is a novel adipokine with significantly elevated expression in the visceral fat of obese patients. DPP-IV is a molecule that regulates metabolic homeostasis and inflammatory processes. Through its enzymatic activity, it plays a significant part in achieving hypoglycemic and weight loss effects through various pathways. DPP-IV and DPP-IV inhibitors also have pleiotropic effects in modulating obesity-related diseases by reducing obesity-related inflammation, ameliorating inflammatory bowel disease (IBD), improving hepatic steatosis and lowering cardiovascular risk, and even decreasing the risk of novel coronavirus disease-19 (COVID-19). This paper reviews the mechanisms of action based on DPP-IV targets in obesity and metabolic homeostasis, as well as their active role in the treatment of chronic diseases associated with obesity.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0753332224013507","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Along with social development and lifestyle changes, the number of overweight and obese patients worldwide is rising annually. Obesity is a chronic metabolic disease with complex etiology. Dipeptidyl peptidase IV (DPP-IV) is a novel adipokine with significantly elevated expression in the visceral fat of obese patients. DPP-IV is a molecule that regulates metabolic homeostasis and inflammatory processes. Through its enzymatic activity, it plays a significant part in achieving hypoglycemic and weight loss effects through various pathways. DPP-IV and DPP-IV inhibitors also have pleiotropic effects in modulating obesity-related diseases by reducing obesity-related inflammation, ameliorating inflammatory bowel disease (IBD), improving hepatic steatosis and lowering cardiovascular risk, and even decreasing the risk of novel coronavirus disease-19 (COVID-19). This paper reviews the mechanisms of action based on DPP-IV targets in obesity and metabolic homeostasis, as well as their active role in the treatment of chronic diseases associated with obesity.

查看原文本刊更多论文

DPP-IV 作为抗肥胖和肥胖相关疾病治疗的潜在候选药物

随着社会的发展和生活方式的改变，全球超重和肥胖患者的数量逐年上升。肥胖症是一种病因复杂的慢性代谢性疾病。二肽基肽酶 IV（DPP-IV）是一种新型脂肪因子，在肥胖患者内脏脂肪中的表达明显升高。DPP-IV 是一种调节代谢平衡和炎症过程的分子。通过其酶活性，它在通过各种途径实现降糖和减肥效果方面发挥着重要作用。DPP-IV 和 DPP-IV 抑制剂在调节肥胖相关疾病方面还具有多效应，如减少肥胖相关炎症、改善炎症性肠病（IBD）、改善肝脂肪变性和降低心血管风险，甚至降低新型冠状病毒病-19（COVID-19）的风险。本文回顾了基于 DPP-IV 靶点在肥胖和代谢平衡中的作用机制，以及它们在治疗肥胖相关慢性疾病中的积极作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedicine & Pharmacotherapy 医学-药学

CiteScore

11.90

自引率

2.70%

发文量

1621

审稿时长

48 days

期刊介绍： Biomedicine & Pharmacotherapy stands as a multidisciplinary journal, presenting a spectrum of original research reports, reviews, and communications in the realms of clinical and basic medicine, as well as pharmacology. The journal spans various fields, including Cancer, Nutriceutics, Neurodegenerative, Cardiac, and Infectious Diseases.